Primary Care Reports articles from April 2004

Primary Care Reports archives from April 2004

Osteoporosis.
April 1, 2004... Osteoporosis is the most common bone disease. It is a major risk factor for fracture, which leads to considerable morbidity, mortality, and expense. (1) Osteoporosis is a global problem that will increase in significance with the growing...

Physician CME questions.
April 1, 2004... 13. What is the most common cause of secondary osteoporosis? A. Hypogonadism B. Glucocorticoids C. Multiple myeloma D. Celiac disease 14. Based on DXA scans, osteopenia is defined as: A. T score between 1 and 3 less...

Correction.(Correction Notice)
April 1, 2004... The February 2004 issue of Primary Care Reports listed two CME answers incorrectly. The correct answer to question 6 is A. In question 7, the answers D and E are not in the correct order. The answer to question 7 is "All of the above," which is...

Risk of adenocarcinoma in Barrett's esophagus.(Brief Article)
April 1, 2004... Although detection of esophageal adenocarcinoma (E-CA) has become routine, the cost efficacy of this intervention is only scantily described. Population data from Northern Ireland include all incident cancers. Murray and colleagues...

Long-term effect of doxazosin, finasteride, and combination for BPH.(Benign Prostatic hyperplasia)(Brief Article)
April 1, 2004... BENIGN PROSTATIC HYPERPLASIA (BPH) is commonly treated with alpha blockers such as doxazosin (DOX), alpha reductase inhibitors such as finasteride (FIN), or both. Long-term trials of DOX and FIN in combination have not been previously available...

Once daily valacyclovir to reduce herpes transmission.(Brief Article)
April 1, 2004... AMONG GENITAL HERPES (HSV-2) discordant couples in whom one partner is HSV-2 infected and the other has not been, several strategies have been used to reduce likelihood of transmission to the uninfected partner. None of the strategies, save...

Use of b-type natriuretic peptide in the evaluation and management of acute dyspnea.(brain natriuretic peptide)(Brief Article)
April 1, 2004... THE ETIOLOGY OF ACUTE DYSPNEA (DSP) can be diverse, and it is often especially difficult to separate pulmonary from cardiac causes. Recently, brain natriuretic peptide (BNP)--so called because of its original identification in porcine...

Association between C-reactive protein and age-related macular degeneration.(Brief Article)
April 1, 2004... AGE-RELATED MACULAR DEGENERATION (AMD) is an important cause of loss of visual acuity, and because there are few effective treatments, enhanced prevention is paramount. The association between some cardiovascular risk factors (eg, smoking,...

VZV reactivation in astronauts.(Varicella Zoster Virus)(Brief Article)
April 1, 2004... STRESS IS A KNOWN TRIGGER FOR reactivation of herpes viruses. Just the physical and psychological trauma of swapping alpha-male mice between 2 mouse colonies and the resultant battle for new alpha-male-dom has been shown to trigger reactivation...

Estrogen found to not affect heart disease, breast cancer.(Pharmacology Watch)
April 1, 2004... The NIH has halted the estrogen-alone wing of the Women's Health Initiative (WHI) a year before its scheduled end. The 11,000 postmenopausal women who have had a hysterectomy and were enrolled in the estrogen-alone trial recently received a...

Vardenafil and ED: a urology perspective on the U.S. pivotal study.(Erectile Dysfunction Alert)
April 1, 2004... VARDENAFIL, A NEW PHOSPHODIESTERASE-5 inhibitor, recently has been approved by the Food and Drug Administration (FDA) for use in the treatment of men with erectile dysfunction (ED). FDA approval resulted from careful consideration of data from...

Vardenafil safely and consistently improved all efficacy parameters.(Erectile Dysfunction Alert)
April 1, 2004... MORE THAN HALF OF AMERICAN MEN OLDER THAN 40 years of age will surfer from erectile dysfunction (ED). ED is associated with increasing age and may coexist with other comorbidities, including arterial hypertension, ischemic heart disease,...

Vardenafil for ED after radical retropubic prostatectomy: a Urologist's view.(Erectile Dysfunction Alert)
April 1, 2004... ERECTILE DYSFUNCTION (ED) IS A COMMON AND ubiqitous problem among men older than 50 years of age. Many men in this age group are at risk for carcinoma of the prostate and undergo surgical treatment for this common male malignancy. Post-radical...

Vardenafil for ED after radical retropubic prostatectomy: a PCP's view.(Erectile Dysfunction Alert)
April 1, 2004... BROCK AND COLLEAGUES RECENTLY PUBLISHED a study confirming the efficacy of vardenafil in the treatment of moderate and severe erectile dysfunction (ED) following nerve-sparing radical prostatectomy. The authors reported that ED following...

Vardenafil for ED after radical retropubic prostatectomy: an endocrinologist's view.(Erectile Dysfunction Alert)
April 1, 2004... MORE THAN ONE-THIRD OF SEXUALLY ACTIVE MEN undergoing nerve-sparing radical retropubic prostatectomy become impotent. With the advent of sildenafil, many are reported to achieve improved erectile function (EF), but most published reports have...

Erectile dysfunction in men with diabetes: a commentary.(Erectile Dysfunction Alert)
April 1, 2004... ERECTILE DYSFUNCTION (ED) IS A COMMON PROBLEM in male patients with diabetes. ED may appear early in the life of a patient with diabetes, as a comorbid condition and correlates with advancing age. Importantly, ED is directly related to poor...